

# Timothy J Perren

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1663946/timothy-j-perren-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

116  
papers

8,358  
citations

44  
h-index

91  
g-index

120  
ext. papers

9,512  
ext. citations

7.2  
avg, IF

5.42  
L-index

#	Paper	IF	Citations
116	Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response. <i>British Journal of Radiology</i> , <b>2021</b> , 94, 20201396	3.4	0
115	Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7). <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkaa026	4.6	5
114	Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 969-977	21.7	13
113	Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 213-220	3.5	9
112	High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum. <i>Cancer</i> , <b>2019</b> , 125, 2772-2781	6.4	11
111	An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. <i>Gynecologic Oncology</i> , <b>2019</b> , 153, 541-548	4.9	37
110	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , <b>2019</b> , 30, 766-773	10.3	46
109	Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data From the EORTC 55971 and CHORUS Trials. <i>Obstetrical and Gynecological Survey</i> , <b>2019</b> , 74, 156-158	2.4	2
108	Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , <b>2019</b> , 152, 53-60	4.9	26
107	A functional form for a representative individual arterial input function measured from a population using high temporal resolution DCE MRI. <i>Magnetic Resonance in Medicine</i> , <b>2019</b> , 81, 1955-1963	4.4	9
106	The clinical impact of using complex molecular profiling strategies in routine oncology practice. <i>Oncotarget</i> , <b>2018</b> , 9, 20282-20293	3.3	8
105	Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1680-1687	21.7	105
104	Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3794-3801	12.9	62
103	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1688-1700	21.7	328
102	Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5506-5506	2.2	8
101	30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1203-16	21.7	88
100	Serial MRI scans help in assessing early response to neoadjuvant chemotherapy and tailoring breast cancer treatment. <i>European Journal of Surgical Oncology</i> , <b>2016</b> , 42, 965-72	3.6	9

99	The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy. <i>Oncotarget</i> , <b>2016</b> , 7, 47927-47937	3.3	16
98	Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist. <i>European Journal of Cancer</i> , <b>2016</b> , 60, 40-8	7.5	36
97	Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , <b>2016</b> , 387, 1066-1074	4.0	170
96	Mucinous epithelial ovarian carcinoma. <i>Annals of Oncology</i> , <b>2016</b> , 27 Suppl 1, i53-i57	10.3	60
95	The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial. <i>Value in Health</i> , <b>2016</b> , 19, 431-9	3.3	15
94	Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK. <i>Clinical Oncology</i> , <b>2016</b> , 28, 760-765	2.8	3
93	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 928-36	21.7	475
92	Discordance between the results and conclusions of ICON7 - Authors'Reply. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, e478-9	21.7	1
91	Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. <i>Lancet, The</i> , <b>2015</b> , 386, 249-57	4.0	705
90	Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5528-5528	2.2	16
89	Exploratory outcome analyses according to stage and residual disease in the ICON7 trial of front-line carboplatin/paclitaxel (CP) ± bevacizumab (BEV) for ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5548-5548	2.2	4
88	Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5502-5502	2.2	54
87	Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5509-5509	2.2	14
86	ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal	2.2	3
85	Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 236-43	21.7	105
84	Targeted anti-vascular therapies for ovarian cancer: current evidence. <i>British Journal of Cancer</i> , <b>2013</b> , 108, 250-8	8.7	58
83	Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5500-5500	2.2	41
82	Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents. <i>Current Oncology Reports</i> , <b>2012</b> , 14, 509-18	6.3	8

81	Mucinous tumours of the ovary. <i>Journal of Clinical Pathology</i> , <b>2012</b> , 65, 580-4	3.9	24
80	A phase 3 trial of bevacizumab in ovarian cancer. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 2484-96	59.2	1454
79	The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. <i>Archives of Gynecology and Obstetrics</i> , <b>2011</b> , 284, 221-7 <sup>5</sup>	2.2	24
78	Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3798-804	2.2	182
77	Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. <i>Oncologist</i> , <b>2011</b> , 16, 1092-100	5.7	181
76	A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. <i>Annals of Oncology</i> , <b>2011</b> , 22, 2411-2416	10.3	23
75	Anthracycline-induced cardiomyopathy in siblings with early breast cancer. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1692	10.3	7
74	Recent EORTC and MRC UK studies: implications for imaging ovarian cancer. <i>Cancer Imaging</i> , <b>2010</b> , 10, 135-6	5.6	2
73	A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1623-1629	10.3	6
72	WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 818-25	7.5	22
71	First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 2020-6	7.5	3
70	Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 122, 787-94	4.4	10
69	Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 64, 407-12	3.5	2
68	Timing of breast cancer surgery in relation to menstrual cycle phase: no effect on 3-year prognosis: the ITS Study. <i>British Journal of Cancer</i> , <b>2008</b> , 98, 39-44	8.7	12
67	Development of antiangiogenic agents for ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2008</b> , 8, 21-32	3.5	4
66	Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3859-65	2.2	442
65	Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 7370-9	12.9	76
64	p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. <i>Annals of Oncology</i> , <b>2007</b> , 18, 997-1003	10.3	45

63	Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. <i>Journal of the National Cancer Institute</i> , <b>2007</b> , 99, 516-25	9.7	71
62	Women with peritoneal carcinomatosis of unknown origin: Efficacy of image-guided biopsy to determine site-specific diagnosis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2007</b> , 114, 46-50	3.7	27
61	Image-guided biopsy in women with breast cancer presenting with peritoneal carcinomatosis. <i>International Journal of Gynecological Cancer</i> , <b>2006</b> , 16 Suppl 1, 108-10	3.5	13
60	Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: a phase I trial in patients with recurrent ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2006</b> , 16, 507-14	3.5	9
59	Implications of ejection fraction value for trastuzumab. <i>BMJ, The</i> , <b>2006</b> , 333, 704	5.9	
58	Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2988-95	2.2	147
57	Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 1076-83	9.7	56
56	Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study. <i>British Journal of Cancer</i> , <b>2004</b> , 90, 2131-4	8.7	3
55	A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. <i>British Journal of Cancer</i> , <b>2004</b> , 91, 627-32	8.7	18
54	Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. <i>British Journal of Cancer</i> , <b>2004</b> , 91, 621-6	8.7	72
53	A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. <i>Annals of Oncology</i> , <b>2004</b> , 15, 751-8	10.3	55
52	Feasibility and compliance of automated measurement of quality of life in oncology practice. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 374-82	2.2	97
51	Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation. <i>British Journal of Cancer</i> , <b>2003</b> , 88, 1578-83	8.7	38
50	Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?. <i>British Journal of Cancer</i> , <b>2002</b> , 87, 1365-9	8.7	5
49	Routine chest radiography following imaging-guided placement of tunneled central lines: a waste of time, money, and radiation. <i>Nutrition in Clinical Practice</i> , <b>2002</b> , 17, 105-9	3.6	6
48	Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. <i>Lancet, The</i> , <b>2002</b> , 360, 505-15	4.0	429
47	The role of topoisomerase inhibitors in gynaecological oncology. <i>Reviews in Gynaecological Practice</i> , <b>2002</b> , 2, 29-34		2
46	Peritoneal carcinomatosis: image-guided peritoneal core biopsy for tumor type and patient care. <i>Radiology</i> , <b>2001</b> , 221, 173-7	20.5	65

45	Self-reported quality of life of individual cancer patients: concordance of results with disease course and medical records. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 2064-73	2.2	76
44	Phase II clinical trials of cisplatin-then-paclitaxel and paclitaxel-then-cisplatin in patients with previously untreated advanced epithelial ovarian cancer. <i>Annals of Oncology</i> , <b>2000</b> , 11, 1603-8	10.3	2
43	Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects. <i>Cytokine</i> , <b>2000</b> , 12, 388-96	4	13
42	Gastroduodenal obstruction from ovarian cancer: imaging features and clinical outcome. <i>Clinical Radiology</i> , <b>2000</b> , 55, 264-72	2.9	19
41	Automated collection of quality-of-life data: a comparison of paper and computer touch-screen questionnaires. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 998-1007	2.2	278
40	Sexual activity questionnaires in clinical trials: acceptability to patients with gynaecological disorders. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>1999</b> , 106, 50-4	3.7	38
39	Supradiaphragmatic manifestations of papillary serous adenocarcinoma of the ovary. <i>Clinical Radiology</i> , <b>1999</b> , 54, 748-54	2.9	27
38	Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20. <i>International Journal of Cancer</i> , <b>1998</b> , 79, 288-93	7.5	94
37	CT demonstration of calcified metastatic mediastinal lymph nodes. <i>Clinical Radiology</i> , <b>1998</b> , 53, 932	2.9	3
36	CT appearances and prognostic significance of splenic metastasis in ovarian cancer. <i>Clinical Radiology</i> , <b>1998</b> , 53, 417-21	2.9	13
35	Endocrine aspects of the clinical management of breast cancer - current issues. <i>Endocrine-Related Cancer</i> , <b>1998</b> , 5, 97-110	5.7	8
34	Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20 <b>1998</b> , 79, 288		2
33	Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. <i>Annals of Oncology</i> , <b>1997</b> , 8, 569-73	10.3	131
32	Good manners for the pharmaceutical industry. <i>Lancet, The</i> , <b>1997</b> , 350, 370-1	40	2
31	A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. <i>British Journal of Cancer</i> , <b>1997</b> , 75, 423-6	8.7	4
30	Effects of interleukin 6 administration on platelets and haemopoietic progenitor cells in peripheral blood. <i>Cytokine</i> , <b>1996</b> , 8, 717-23	4	24
29	Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. <i>Journal of Clinical Oncology</i> , <b>1996</b> , 14, 2280-8	2.2	67
28	Phospholipase A2 activity in serum is induced during treatment with recombinant human interleukin-6 in patients with cancer. <i>Annals of Clinical Biochemistry</i> , <b>1996</b> , 33 ( Pt 6), 565-7	2.2	5

27	A phase II study of single agent paclitaxel in patients at first relapse following initial chemotherapy for breast cancer. <i>Clinical Oncology</i> , <b>1996</b> , 8, 358-62	2.8	5
26	The timing of breast cancer surgery with respect to the menstrual cycle. More data which emphasize the need for a prospective study. <i>Breast</i> , <b>1995</b> , 4, 1-3	3.6	3
25	Metastatic breast carcinoma involving the gastric antrum and duodenum: computed tomography appearances. <i>British Journal of Radiology</i> , <b>1995</b> , 68, 970-2	3.4	13
24	Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. <i>British Journal of Cancer</i> , <b>1995</b> , 72, 1016-9	8.7	52
23	Management of breast cancer. Refer women to multidisciplinary breast clinics. <i>BMJ: British Medical Journal</i> , <b>1994</b> , 308, 714-5		1
22	A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group. <i>British Journal of Cancer</i> , <b>1993</b> , 68, 1190-4	8.7	8
21	Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferon. <i>Annals of Oncology</i> , <b>1993</b> , 4, 515-6	10.3	16
20	The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. <i>British Journal of Cancer</i> , <b>1993</b> , 67, 1132-5	8.7	51
19	Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. <i>British Journal of Cancer</i> , <b>1993</b> , 68, 122-4	8.7	257
18	High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease. <i>European Journal of Cancer</i> , <b>1992</b> , 28A, 1396-400	7.5	14
17	Lymphomas of the cervix and upper vagina: a report of five cases and a review of the literature. <i>Gynecologic Oncology</i> , <b>1992</b> , 44, 87-95	4.9	64
16	Phase II trial of trimelamol in refractory ovarian cancer. <i>British Journal of Cancer</i> , <b>1991</b> , 63, 311-3	8.7	11
15	Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease. <i>British Journal of Cancer</i> , <b>1990</b> , 61, 919-23	8.7	14
14	ChlVPP combination chemotherapy for Hodgkin's disease: long-term results. <i>British Journal of Cancer</i> , <b>1990</b> , 62, 279-85	8.7	72
13	The value of computed tomographic (CT) scan surveillance in the detection and management of brain metastases in patients with small cell lung cancer. <i>British Journal of Cancer</i> , <b>1990</b> , 62, 684-6	8.7	37
12	Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. <i>British Journal of Cancer</i> , <b>1990</b> , 61, 330-4	8.7	50
11	Carboplatin and ifosfamide in ovarian cancer phase II and III trials. London Gynaecological Oncology Group. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1990</b> , 26 Suppl, S48-50	3.5	2
10	Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>1990</b> , 8, 899-905	2.2	52

9	Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1989</b> , 23, 373-6	3.5	30
8	High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease. <i>British Journal of Cancer</i> , <b>1989</b> , 59, 631-5	8.7	49
7	The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. <i>British Journal of Cancer</i> , <b>1989</b> , 59, 434-8	8.7	88
6	High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. <i>British Journal of Cancer</i> , <b>1988</b> , 58, 779-82	8.7	49
5	Phase II study of Zoladex depot in advanced prostatic cancer with special reference to criteria of response and survival. <i>British Journal of Urology</i> , <b>1987</b> , 60, 436-42		11
4	Multiple myeloma treated with high dose intravenous melphalan. <i>British Journal of Haematology</i> , <b>1987</b> , 66, 55-62	4.5	174
3	Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1986</b> , 18, 39-43	3.5	30
2	Assessment of bleomycin, adriamycin and mitomycin-C in the treatment of recurrent cervical cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>1985</b> , 92, 756-61	3.7	5
1	A radioimmunoassay for GnRH agonist analogue in serum of patients with prostate cancer treated with D-Ser (tBu) <sub>6</sub> AZA Gly <sub>10</sub> GnRH. <i>Clinical Endocrinology</i> , <b>1985</b> , 22, 453-62	3.4	25